Orexo AB (publ) (ORX.ST)
SEK 20.8
(-5.24%)
SEK 20.8
(-5.24%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -128.3 Million SEK | 27.76% |
| 2022 | -177.6 Million SEK | 20.54% |
| 2021 | -223.5 Million SEK | -164.81% |
| 2020 | -84.4 Million SEK | -138.52% |
| 2019 | 219.1 Million SEK | 58.88% |
| 2018 | 137.9 Million SEK | 494.4% |
| 2017 | 23.2 Million SEK | -20.0% |
| 2016 | 29 Million SEK | 114.65% |
| 2015 | -197.98 Million SEK | -249.9% |
| 2014 | -56.58 Million SEK | 63.48% |
| 2013 | -154.93 Million SEK | -80.45% |
| 2012 | -85.86 Million SEK | 78.1% |
| 2011 | -392 Million SEK | -339.25% |
| 2010 | -89.24 Million SEK | 9.01% |
| 2009 | -98.07 Million SEK | 4.83% |
| 2008 | -103.05 Million SEK | 0.0% |
| 2007 | - SEK | 100.0% |
| 2006 | -32.94 Million SEK | 23.83% |
| 2005 | -43.24 Million SEK | -171.26% |
| 2004 | -15.94 Million SEK | 42.22% |
| 2003 | -27.59 Million SEK | -32.64% |
| 2002 | -20.8 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -8.9 Million SEK | 52.15% |
| 2024 Q2 | -35.9 Million SEK | -303.37% |
| 2024 Q3 | -41.9 Million SEK | -16.71% |
| 2023 Q3 | -33.3 Million SEK | -164.29% |
| 2023 Q4 | -18.6 Million SEK | 44.14% |
| 2023 FY | -128.3 Million SEK | 27.76% |
| 2023 Q2 | -12.6 Million SEK | 80.28% |
| 2023 Q1 | -63.9 Million SEK | 30.39% |
| 2022 Q1 | -23.6 Million SEK | 64.19% |
| 2022 Q2 | -35.7 Million SEK | -51.27% |
| 2022 Q3 | -26.5 Million SEK | 25.77% |
| 2022 Q4 | -91.8 Million SEK | -246.42% |
| 2022 FY | -177.6 Million SEK | 20.54% |
| 2021 FY | -223.5 Million SEK | -164.81% |
| 2021 Q1 | -31.5 Million SEK | 36.49% |
| 2021 Q2 | -73.7 Million SEK | -133.97% |
| 2021 Q4 | -65.9 Million SEK | -26.73% |
| 2021 Q3 | -52 Million SEK | 29.44% |
| 2020 Q3 | -84.9 Million SEK | -161.23% |
| 2020 Q1 | 82.6 Million SEK | 112.89% |
| 2020 FY | -84.4 Million SEK | -138.52% |
| 2020 Q2 | -32.5 Million SEK | -139.35% |
| 2020 Q4 | -49.6 Million SEK | 41.58% |
| 2019 Q2 | 54.6 Million SEK | 287.23% |
| 2019 Q3 | 111.7 Million SEK | 104.58% |
| 2019 Q4 | 38.8 Million SEK | -65.26% |
| 2019 FY | 219.1 Million SEK | 58.88% |
| 2019 Q1 | 14.1 Million SEK | -72.62% |
| 2018 Q3 | 62.2 Million SEK | 24.15% |
| 2018 FY | 137.9 Million SEK | 494.4% |
| 2018 Q2 | 50.1 Million SEK | 293.44% |
| 2018 Q4 | 51.5 Million SEK | -17.2% |
| 2018 Q1 | -25.9 Million SEK | -197.0% |
| 2017 Q3 | 28.2 Million SEK | 809.68% |
| 2017 Q2 | 3.1 Million SEK | 108.96% |
| 2017 Q1 | -34.6 Million SEK | -203.9% |
| 2017 FY | 23.2 Million SEK | -20.0% |
| 2017 Q4 | 26.7 Million SEK | -5.32% |
| 2016 FY | 29 Million SEK | 114.65% |
| 2016 Q3 | 36 Million SEK | 620.0% |
| 2016 Q2 | 5 Million SEK | 114.49% |
| 2016 Q1 | -34.5 Million SEK | 33.4% |
| 2016 Q4 | 33.3 Million SEK | -7.5% |
| 2015 FY | -197.98 Million SEK | -249.9% |
| 2015 Q1 | -15.5 Million SEK | -130.03% |
| 2015 Q2 | -84.6 Million SEK | -445.81% |
| 2015 Q3 | -46.1 Million SEK | 45.51% |
| 2015 Q4 | -51.8 Million SEK | -12.36% |
| 2014 Q2 | -50.2 Million SEK | -137.91% |
| 2014 Q4 | 51.61 Million SEK | 240.26% |
| 2014 FY | -56.58 Million SEK | 63.48% |
| 2014 Q3 | -36.8 Million SEK | 26.69% |
| 2014 Q1 | -21.1 Million SEK | 44.23% |
| 2013 Q1 | 27.5 Million SEK | 223.52% |
| 2013 Q2 | -115.7 Million SEK | -520.73% |
| 2013 Q4 | -37.83 Million SEK | -30.92% |
| 2013 Q3 | -28.9 Million SEK | 75.02% |
| 2013 FY | -154.93 Million SEK | -80.45% |
| 2012 FY | -85.86 Million SEK | 78.1% |
| 2012 Q4 | -22.26 Million SEK | 27.72% |
| 2012 Q2 | -16.6 Million SEK | -2.47% |
| 2012 Q3 | -30.8 Million SEK | -85.54% |
| 2012 Q1 | -16.2 Million SEK | 94.02% |
| 2011 FY | -392 Million SEK | -339.25% |
| 2011 Q4 | -270.98 Million SEK | -385.0% |
| 2011 Q3 | -55.87 Million SEK | -115.01% |
| 2011 Q2 | -25.98 Million SEK | 33.64% |
| 2011 Q1 | -39.16 Million SEK | -1938.54% |
| 2010 Q3 | -28.5 Million SEK | 19.27% |
| 2010 Q1 | -27.56 Million SEK | 52.5% |
| 2010 FY | -89.24 Million SEK | 9.01% |
| 2010 Q2 | -35.3 Million SEK | -28.09% |
| 2010 Q4 | 2.13 Million SEK | 107.47% |
| 2009 FY | -98.07 Million SEK | 4.83% |
| 2009 Q1 | 26.32 Million SEK | 282.36% |
| 2009 Q2 | -56.83 Million SEK | -315.94% |
| 2009 Q3 | -9.53 Million SEK | 83.22% |
| 2009 Q4 | -58.02 Million SEK | -508.52% |
| 2008 Q3 | 1.88 Million SEK | 0.0% |
| 2008 Q4 | -14.43 Million SEK | -866.08% |
| 2008 FY | -103.05 Million SEK | 0.0% |
| 2007 FY | - SEK | 100.0% |
| 2006 FY | -32.94 Million SEK | 23.83% |
| 2005 FY | -43.24 Million SEK | -171.26% |
| 2004 FY | -15.94 Million SEK | 42.22% |
| 2003 FY | -27.59 Million SEK | -32.64% |
| 2002 FY | -20.8 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AcuCort AB | -13.69 Million SEK | -837.112% |
| AlzeCure Pharma AB (publ) | -37.16 Million SEK | -245.199% |
| BioGaia AB (publ) | 365.35 Million SEK | 135.117% |
| Enzymatica AB (publ) | -49.72 Million SEK | -158.004% |
| Enorama Pharma AB (publ) | -44.61 Million SEK | -187.584% |
| Gabather AB (publ) | -9.43 Million SEK | -1259.542% |
| Klaria Pharma Holding AB (publ.) | -35.78 Million SEK | -258.54% |
| Moberg Pharma AB (publ) | -21.09 Million SEK | -508.259% |
| Nanexa AB (publ) | -76.39 Million SEK | -67.936% |
| Newbury Pharmaceuticals AB (publ) | -15.4 Million SEK | -732.846% |
| ODI Pharma AB | 355.97 Thousand SEK | 36142.262% |
| Probi AB (publ) | 16.81 Million SEK | 862.828% |
| Swedencare AB (publ) | 58.6 Million SEK | 318.942% |
| Swedish Orphan Biovitrum AB (publ) | 2.4 Billion SEK | 105.326% |
| Toleranzia AB | -7.45 Million SEK | -1620.07% |
| Vivesto AB | -367.03 Million SEK | 65.044% |